Axogen, Inc. — Director's Dealing 2015

Feb 12, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AxoGen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2015-02-10

Reporting Person: Freitag Gregory Gene (Director, General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-02-10	Common Stock	A	4800	$2.75	Acquired	48902	Direct

Footnotes

F1: The reporting person purchased these shares in their individual capacity and not through any directed share or other formal program in connection with an underwritten registered public offering of the Company. On February 5, 2015, the trade date for the public offering, the closing sale price reported by NASDAQ was $3.16 per share. The public offering closed on February 10, 2015, and the closing sale price reported by NASDAQ on such date was $3.18 per share.